A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.

The invention relates to pharmaceutical matrix tablets for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-1V-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1//-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide. The matrix tablets reliably provide extended release of the bradykinin B2 receptor antagonist which makes them particularly suitable for prophylactic and/or chronic therapies. Therapeutic uses of the matrix tablets are provided.

##STR00001##

The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-/V-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1/f-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(di-fluoromethoxy)acetamide. The solid dispersions comprise the BK B2 receptor antagonist in the amorphous form and homogeneously dispersed in a pharmaceutically acceptable polymer. Furthermore, methods for preparation and uses of the solid dispersions, including therapeutic uses, are provided.

##STR00001##